Chieko Sakai1, Sunao Abe2, Minoru Kouzuki3, Hisashi Shimohiro4, Yoshie Ota5, Hironori Sakinada5, Tatsuo Takeuchi6, Tsuyoshi Okura7, Takeshi Kasagi2, Keiichi Hanaki8. 1. Department of Adult and Elderly Nursing, School of Health Sciences, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. 2. †Marine Products Kimuraya Co., Ltd., Sakaiminato 684-0072, Japan. 3. ‡Department of Biological Regulation, School of Health Sciences, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. 4. §Department of Pathobiological Science and Technology, School of Health Sciences, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. 5. ||Clinical Laboratory Department, Hakuai Hospital, Yonago 683-0853, Japan. 6. ¶Department of Endocrinology and Metabolism, Hakuai Hospital, Yonago 683-0853, Japan. 7. *Division of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. 8. ††Department of Women's and Children's Family Nursing, School of Health Sciences, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.
Abstract
BACKGROUND: Fucoidan is derived from seaweed widely used in Japanese cuisine, but little is known about its influence on glucose metabolism. To obtain information about the physiological effects of fucoidan on glucose metabolism, the digestive system, and the gustatory system controlling taste sensation in patients with type 2 diabetes, we conducted a randomized, double-blind, placebo-controlled study. METHODS: Thirty patients with type 2 diabetes on diet therapy were recruited from an outpatient clinic (22 men and 8 women aged 59.10 ± 13.24 years, body mass index: 25.18 ± 3.88, hemoglobin A1c: 7.04 ± 1.24%). They were divided into 2 groups and underwent 2 interventions with a 4-week interval. One group received fucoidan for 12 weeks (a daily 60 mL test beverage containing 1,620 mg of fucoidan) and then placebo (60 mL) for the subsequent 12-week period, while the order was reversed in the other group. Evaluation was performed just before and after each intervention. Taste sensitivity was measured for 5 basic tastes by the filter paper disk method and food intake was evaluated with a validated diet questionnaire. RESULTS: No adverse events occurred during the study period. Despite no change of the diet, stool frequency increased during fucoidan intake (from 7.78 ± 4.64/week in Week 1 to 9.15 ± 5.03/week in Week 5, P < 0.001), and it increased more in lean subjects. In 11 subjects whose stool frequency exceeded the mean value, the thresholds for sweet, salty, bitter and umami tastes were significantly reduced (enhancement of sensitivity) after fucoidan intake. In 14 subjects with normal HOMA-IR (homeostatic model assessment of insulin resistance, < 2.5), hemoglobin A1c decreased after fucoidan intake (from 6.73 ± 1.00 to 6.59 ± 1.00%, P < 0.05), as did the fasting plasma level of GLP-1 (glucagon-like peptide-1, from 6.42 ± 3.52 to 4.93 ± 1.88 pmol/L, P < 0.05). CONCLUSION: Sustained fucoidan intake led to alterations of gastrointestinal function, including increased stool frequency and enhanced taste sensitivity, which could contribute to better control of diabetes.
BACKGROUND: Fucoidan is derived from seaweed widely used in Japanese cuisine, but little is known about its influence on glucose metabolism. To obtain information about the physiological effects of fucoidan on glucose metabolism, the digestive system, and the gustatory system controlling taste sensation in patients with type 2 diabetes, we conducted a randomized, double-blind, placebo-controlled study. METHODS: Thirty patients with type 2 diabetes on diet therapy were recruited from an outpatient clinic (22 men and 8 women aged 59.10 ± 13.24 years, body mass index: 25.18 ± 3.88, hemoglobin A1c: 7.04 ± 1.24%). They were divided into 2 groups and underwent 2 interventions with a 4-week interval. One group received fucoidan for 12 weeks (a daily 60 mL test beverage containing 1,620 mg of fucoidan) and then placebo (60 mL) for the subsequent 12-week period, while the order was reversed in the other group. Evaluation was performed just before and after each intervention. Taste sensitivity was measured for 5 basic tastes by the filter paper disk method and food intake was evaluated with a validated diet questionnaire. RESULTS: No adverse events occurred during the study period. Despite no change of the diet, stool frequency increased during fucoidan intake (from 7.78 ± 4.64/week in Week 1 to 9.15 ± 5.03/week in Week 5, P < 0.001), and it increased more in lean subjects. In 11 subjects whose stool frequency exceeded the mean value, the thresholds for sweet, salty, bitter and umami tastes were significantly reduced (enhancement of sensitivity) after fucoidan intake. In 14 subjects with normal HOMA-IR (homeostatic model assessment of insulin resistance, < 2.5), hemoglobin A1c decreased after fucoidan intake (from 6.73 ± 1.00 to 6.59 ± 1.00%, P < 0.05), as did the fasting plasma level of GLP-1 (glucagon-like peptide-1, from 6.42 ± 3.52 to 4.93 ± 1.88 pmol/L, P < 0.05). CONCLUSION: Sustained fucoidan intake led to alterations of gastrointestinal function, including increased stool frequency and enhanced taste sensitivity, which could contribute to better control of diabetes.
Authors: John P Bantle; Judith Wylie-Rosett; Ann L Albright; Caroline M Apovian; Nathaniel G Clark; Marion J Franz; Byron J Hoogwerf; Alice H Lichtenstein; Elizabeth Mayer-Davis; Arshag D Mooradian; Madelyn L Wheeler Journal: Diabetes Care Date: 2008-01 Impact factor: 19.112
Authors: Patrice D Cani; Jacques Amar; Miguel Angel Iglesias; Marjorie Poggi; Claude Knauf; Delphine Bastelica; Audrey M Neyrinck; Francesca Fava; Kieran M Tuohy; Chantal Chabo; Aurélie Waget; Evelyne Delmée; Béatrice Cousin; Thierry Sulpice; Bernard Chamontin; Jean Ferrières; Jean-François Tanti; Glenn R Gibson; Louis Casteilla; Nathalie M Delzenne; Marie Christine Alessi; Rémy Burcelin Journal: Diabetes Date: 2007-04-24 Impact factor: 9.461
Authors: Matthias B Schulze; Mandy Schulz; Christin Heidemann; Anja Schienkiewitz; Kurt Hoffmann; Heiner Boeing Journal: Arch Intern Med Date: 2007-05-14
Authors: Hyeung-Jin Jang; Zaza Kokrashvili; Michael J Theodorakis; Olga D Carlson; Byung-Joon Kim; Jie Zhou; Hyeon Ho Kim; Xiangru Xu; Sic L Chan; Magdalena Juhaszova; Michel Bernier; Bedrich Mosinger; Robert F Margolskee; Josephine M Egan Journal: Proc Natl Acad Sci U S A Date: 2007-08-27 Impact factor: 11.205
Authors: Gonçalo P Rosa; Wilson R Tavares; Pedro M C Sousa; Aida K Pagès; Ana M L Seca; Diana C G A Pinto Journal: Mar Drugs Date: 2019-12-20 Impact factor: 5.118
Authors: Ciara D Bannon; Julia Eckenberger; William John Snelling; Chloe Elizabeth Huseyin; Philip Allsopp; Conall Strain; Priya Ramnani; Roberto Chitarrari; John Grant; Sarah Hotchkiss; Kevin Philp; Ross Campbell; Kieran Michael Tuohy; Marcus J Claesson; Nigel George Ternan; James S G Dooley; Roy D Sleator; Ian Rowland; Chris I R Gill Journal: Foods Date: 2021-12-03